A Phase 1a/1b Multicentre, Open label, Dose escalation and Dose expansion Study to Evaluate the Safety, Pharmacokinetics, And Antitumor Activity of Ak104 in Subjects with Advanced Solid Tumours
- Markman, Ben (Primary Chief Investigator (PCI))
Project: Research